2002
Mechanism of ErbB1 and ErbB2 Hetero-Oligomerization
Yu J, Lemmon M. Mechanism of ErbB1 and ErbB2 Hetero-Oligomerization. 2002 DOI: 10.21236/ada409630.Peer-Reviewed Original ResearchB cell linesErbB2 interactsBreast cancer therapyAbsence of IL2B cell proliferationIL2 receptor betaBreast cancerReceptor betaERBB2 overexpressionErbB receptor ligandsReceptor ligandsErbB2Cancer therapyValuable targetVivo systemGamma chainIntracellular domainMechanism of activationExtracellular domain
2001
Development of Strategies to Manipulate ErbB Receptor Heterodimerization from a Quantitative Analysis of Receptor/Ligand Relationships
Lemmon M. Development of Strategies to Manipulate ErbB Receptor Heterodimerization from a Quantitative Analysis of Receptor/Ligand Relationships. 2001 DOI: 10.21236/ada398353.Peer-Reviewed Original ResearchBreast cancerErbB-1Growth factorHuman breast cancer casesBreast cancer casesInappropriate receptor activationEpidermal growth factor receptorGrowth factor receptorSame growth factorsCancer casesReceptor activationExtracellular domainReceptor heterodimerizationReceptor tyrosine kinasesFactor receptorErbB receptorsReceptorsErbB2ErbB familyErbB2 activationReceptor transmodulationDevelopment of strategiesCancerTyrosine kinaseReceptor homo